|Bid||180.00 x 1100|
|Ask||189.30 x 800|
|Day's Range||183.84 - 206.82|
|52 Week Range||118.18 - 325.45|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in pat
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 17, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL.
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 15, 2022--BeiGene today announced the launch of a new program, Talk About It: Cancer and Mental Health.